Der Stellenwert von Gemtuzumab Ozogamicin (GO) in der Kombination mit Chemotherapie für die Behandlung der akuten myeloischen Leukämie (AML) wird derzeit auch in Europa untersucht. Der Einsatz von GO (6 mg/m 2 ) in Kombination mit Cytarabin (100 mg/m 2 ) bei der Primärbehandlung älterer Patienten mit AML wird in der SAL-Phase-II-Studie geprüft. Das in der MRC-AML15-Studie nachgewiesene verbesserte krankheitsfreie Über-leben belegt den Stellenwert von GO (3 mg/m 2 ) in Kombination mit Standard-und hoch dosiertem Cytarabin und einem Anthrazyklin für die Induktion und Konsolidierung bei neu diagnostizierter AML. Insbesondere Patienten mit einem günstigen und intermediären zytogenetischen Risikoprofil scheinen von der Gabe von GO zu profitieren. In der Behandlung von AML-Rezidiven oder refraktärer Erkrankung erwies sich GO (3 mg/m 2 ) als sicher mit hoch dosiertem Cytarabin (3 g/m 2 ) kombinierbar und war in der Wirksamkeit historischen Vergleichskollektiven der AMLSG-Studiengruppe überlegen. Erste Ergebnisse dokumentieren die Möglichkeit einer allogenen Stammzelltransplantation nach GO-Therapie. Erste Daten einer laufenden Studie belegen auch die Einsatzmög-lichkeit und das Sicherheitsprofil von GO als Bestandteil einer Konditionierungstherapie von reduzierter Intensität mit Fludarabin und Ganzkörperbestrahlung.
Introduction
Acute myeloid leukemia (AML) is the most frequent leukemia in adults with an incidence of 3.7 in 100,000. Induction therapy with cytarabine (Ara-C) and an anthracycline achieves a complete remission (CR) in 60-80% of the patients [1] [2] [3] . However, recurrence occurs in the majority of the patients (50-80%). Salvage therapy is not standardized, and only a median of 25% of patients enter a second CR lasting in most cases 6-8 months [4] [5] [6] [7] . 40-50% of the AML patients in 2nd CR achieve a long-term survival after HLA-matched stem cell transplantation (SCT) [8, 9] . However, not every patient qualifies for this treatment approach [10] . After many attempts to improve results with conventional combination chemotherapy, biological agents offer the possibility of an increased response rate [11] . Such therapeutic options include gemtuzumab ozogamicin (GO), which is a humanized monoclonal murine Ig4 antibody (hP67.6) targeting the CD33 antigen. A bifunctional linker conjugates hP67.6 with the antibiotic calicheamicin, which is 1,000 times more cytotoxic than doxorubin. After internalization of the antigenantibody complex, the low pH of the endosome induces hydrolysis of the linker. Calicheamicin binds sequence specific to DNA, leading to DNA double-strand breaks and apoptosis. GO is an attractive substance, as the CD33 glycoprotein is expressed on 90% of AML blasts. CD33 is also present on myeloid precursor cells, macrophages, monocytes and dendritic cells, but not on hematopoietic stem cells, which are necessary for hematopoietic repopulation [12] [13] [14] . Three multicenter phase II trials for relapsed AML were conducted with 2 doses of GO 9 mg/m 2 within 14 days in 277 patients and achieved 13% CR and 13% CR without complete platelet recovery (CRp) [15, 16] . Clinically relevant toxicity was bone marrow suppression and hepatopathy. GO is approved by the Food and Drug Administration (FDA) under the name Mylotarg for monotherapy of relapsed AML in patients older than 60 years and is currently under review for approval at the European Medicines Agency (EMEA). Trials are ongoing that analyze the toxicity profile and the efficacy of GO with combination chemotherapy.
GO Chemotherapy for Relapsed or Refractory AMLthe AMLSG 05-04 Trial
In relapsed and refractory AML several combinations of GO (4-9 mg/m 2 ) with Ara-C (100 mg/m 2 ) containing regimens have been reported [17] [18] [19] [20] [21] [22] . The AMLSG 05-04 trial combines GO (3 mg/m 2 ) with all-trans retinoic acid (ATRA, 45 mg/m 2 day 4-6, 15 mg/m 2 day 7-28), mitoxantrone (12 mg/m 2 day 2, 3) and high-dose Ara-C (3 g/m 2 day 1-3) (GO-A-HAM) in patients < 60 years with refractory AML. The study recruited up to now 76 patients (84 patients planned). In an interim analysis, GO-A-HAM had similar treatment-related Gleissner/Schlenk/Bornhäuser/Berdel lethality as A-HAM (ATRA and HAM), S-HAM (sequential high-dose Ara-C) or HAM (high-dose Ara-C). GO-A-HAM induced a CR in 49% of patients, while A-HAM reached a CR in 34%, S-HAM in 23%, and HAM in 24% of patients. 64% of patients with refractory AML responded to the GO-A-HAM regimen (CR and PR). In a retrospective cohort analysis, treatment with ATRA (p = 0.05) and GO (p = 0.05) correlated with a good prognosis. Median survival after GO-A-HAM accounted for 16.2 months (p = 0.002) as compared to 12.5 months after A-HAM or 7.2 months after S-HAM or HAM [23] .
Randomized Trials for the Treatment of de novo AMLthe SAL Phase II Trial and the MRC AML15 Trial
As the addition of GO to standard chemotherapy 7+3 seemed to be too toxic for elderly patients with AML, the randomized SAL phase II trial compares 7+GO (GO 6 mg/m 2 , day 1; 4 mg/m 2 , day 8 and Ara-C 100 mg/m 2 day 1-7, every 12 h) with 7+3 (daunorubicin 45 mg/m 2 day 1-3 and Ara-C 100 mg/m 2 day 1-7 every 12 h) for induction treatment of AML in patients > 60 years. The trial design provides consolidation with Ara-C 1 g/m 2 every 12 h day 1, 3, 5. This randomized trial has recruited more than 50 patients so far. The trial is open for participation within the German 'Studien-Allianz Leukämien' (SAL) ( fig. 1) . The combination of 7+GO may establish a less cardiotoxic primary treatment for newly diagnosed AML in elderly and frail patients, as far as both regimens reach equal toxicity and efficacy. In patients of all age groups, the MRC AML15 trial analyzed GO (3 mg/m 2 ) for remission induction and consolidation (GO 6 mg/m 2 ). This study is based on a 2 × 2 multifactorial design providing different induction and consolidation treatments with and without GO ( fig. 2 ). So far more than 2,000 patients are recruited into the trial. GO was combined in the induction treatment with either ADE (Ara-C, daunorubicin, etoposide; n = 160), DA (daunorubicin, Ara-C; n = 474) or FLAG-Ida (fludarabine, Ara-C, G-CSF, idarubicin; n = 479) in 1,113 patients (median age: 49 years; cytogenetics: favorable 129, intermediate 631, adverse 132) [24] . No increased liver toxicity was observed after GO therapy; similar recovery times were observed for neutrophils (20 days) and platelets (20 days vs 18 days) with and without GO. Similar CR rates were achieved with and without GO (84% with GO vs 86% without GO). Interestingly, at a median follow-up of 16 months in 964 patients, GO led to fewer relapses (37% vs 52% at 3 years, p = 0.01), resulting in a significantly improved disease-free survival (51% vs 40%, p = 0.008) of the patients with de novo AML. No extra liver toxicity was seen in subsequent stem cell transplantations.
GO and Stem Cell Transplantation
Several trials confirmed feasibility of allogeneic SCT in GOtreated patients. After a GO-containing regimen, CR/CRp patients reached a median survival of > 18.3 months (n = 14) with allogeneic SCT, 16.5 months (n = 11) with autologous SCT, 12.2 months with additional chemotherapy (n = 11), and 11.2 months without further treatment (n = 35; p = 0.007) [16] . The German Study Initiative on Leukemias conducted a phase II trial in relapsed AML with reduced-intensity conditioning therapy. So far, results of 19 patients are available that have been treated with GO (GO 6 mg/m 2 day -21 and GO 3 mg/m 2 day -14), fludarabine (30 mg/m 2 day -3 up to day -1), and total body irradiation (TBI; 800 or 200 cGY depending on the relapse-free interval and age), followed by allogeneic SCT in aplasia. After TBI, 75% of patients reached a CR. Seven patients are alive and in CR. With a median follow-up of 21 months no sinusoidal obstruction syndrome (SOS) and delayed liver toxicity was documented. The probability of overall and disease-free survival at 2 years accounted for 51% and 46%, respectively [25] .
Conclusion

De novo AML
The toxicity profile allows the application of GO together with chemotherapy (table 1) [20, [26] [27] [28] [29] [30] [31] [32] . GO in combination with intensive induction or consolidation therapy was initially analyzed by Kell et al. [28, 33] . GO 3 mg/m 2 proved applicable for induction therapy with daunorubicin and Ara-C or FLAGIda as well as MACE (amsacrine, Ara-C, etoposide) or highdose Ara-C [28] . In the MRC AML15 trial GO (3 mg/m 2 ) reduced the risk of relapse in de novo AML and improved disease-free survival without additional toxicity. Preliminary data indicate that favorable and intermediate cytogenetic risk groups may particularly benefit from addition of GO. Randomized comparisons of GO and Fms-like tyrosine kinase 3 (FLT-3) inhibitors are ongoing in patients with FLT-3 mutations. Results of the randomized German SAL phase II trial are awaited, that analyzes in elderly patients the substitution of daunorubicin by GO in a setting with standard-dose Ara-C (100 mg/m 2 for 5-7 days).
Relapsed and Refractory AML
Single-agent GO therapy (9 mg/m 2 ) is approved for the treatment of relapsed AML. Application of GO (3-9 mg/m 2 ) and chemotherapy (Ara-C 100 mg/m 2 -1 g/m 2 ) achieved CR rates of 12-70% and a median overall survival of 2-11 months in refractory or relapsed AML (table 1) [17] [18] [19] [20] [21] [22] . In line with these results are the data of the AMLSG trial that favor the GO-A-HAM (GO 3 mg/m 2 ) regimen in comparison to other modifications of high-dose Ara-C-containing protocols. Randomized trials are outstanding and data are preliminary. [16] . In the context of myeloablative conditioning chemotherapy, SOS developed in 5/27 (19%) patients transplanted prior to GO. SOS occurred in 8/40 (17%) patients transplanted after GO. GO 2 mg/m 2 was applicable with fludarabine/melphalan before allogeneic SCT [34] . The ongoing German trial supports incorporation of GO in a reduced-intensity conditioning regimen with fludarabine and TBI exploiting the aplastic potential of GO within this indication.
